Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsTSX:LABS FCF Margin % is -4.81% as of Jun. 2026. The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, MediPharm Labs ranks worse than 63.13% on this metric.
The historical data trend for MediPharm Labs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (TSX:LABS) has a FCF Margin % of -4.81% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MediPharm Labs and its competitors. According to the industry distribution chart, MediPharm Labs ranks #606 out of 960 companies in the Drug Manufacturers industry, placing it in the top 63.1%.
Is MediPharm Labs' FCF Margin % too high?
MediPharm Labs' current FCF Margin % is -4.81%. Based on the distribution chart, MediPharm Labs ranks #606 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does MediPharm Labs' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #606 out of 960 companies for FCF Margin %. This places MediPharm Labs in the lower half of its industry. The industry median FCF Margin % is 2.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.47, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current FCF Margin % is -4.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (TSX:LABS) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.07, compared to a current price of C$0.08 — trading 14.3% above its estimated fair value. The current FCF Margin % is -4.81%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MediPharm Labs (TSX:LABS), the current FCF Margin % is -4.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:LABS has been successfully added to your 
